Return on investment 2: evaluating the cost-effectiveness of needle and syringe programs in Australia 2009 has just been published by the National Centre in HIV Epidemiology and Clinical Research, UNSW and the Department of Health and Ageing.
The report comes out very positively in favour of the gains made in these programs from 2000 - 2009, estimating that 32,050 HIV infections and 96,667 HCV infections have been averted. This has meant "substantial healthcare cost savings to government, and substantial gains in disability-adjusted life years ... For every dollar currently spent on the programs, more than four dollars will be returned (in addition to the investment – that is, five times the investment) and approximately 0.2 days of disability-adjusted life gained. Over a longer time horizon there is even greater return."
No comments:
Post a Comment